Sobi's interim report for the first quarter of 2012 will be published on 26 April 2012 at 8.30 a.m. CET.
Conference call at 2.00 p.m. CET
Financial analysts and media are invited to a telephone conference at 2.00 p.m. CET the same day hosted by CEO Geoffrey McDonough and CFO Lars Sandström. The presentation will be held in English.
A recorded version will be available afterwards at www.sobi.com (http://www.sobi.com/) under Investors & Media/Audio cast. Slides used in the presentation will also be available on the web site under Investors & Media/Presentations.
Details for participation
Please call:
Sweden: +46 (0)8 505 597 72
UK: +44 (0)207 750 99 50
US: + 1 866 676 58 70
Yours sincerely,
Åsa Stenqvist,
VP Communications and Investor Relations (Acting)
Phone: +46 8 697 21 88
Swedish Orphan Biovitrum (Sobi)Sobi is a leading integrated biopharmaceutical company dedicated to bringing innovative therapies and services to improve the life of rare disease patients and their families. The product portfolio comprises about 45 marketed products as well as projects in the late clinical phase. Key therapeutic areas are Inflammation and Genetics & Metabolism. In 2011, Sobi had revenues of SEK 1.9 billion and around 500 employees. The share (STO: SOBI) is listed on NASDAQ OMX Stockholm. More information is available at www.sobi.com (http://www.sobi.com/).
The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of the
information contained therein.
Source: Swedish Orphan Biovitrum AB (publ) via Thomson Reuters ONE
